Key result
GLP-1 RAs improve symptoms and reduce CV death or worsening HF in obesity-related HFpEF.
Why the study?
Despite evidence supporting SGLT2 inhibitors and mineralocorticoid receptor antagonists, morbidity and mortality in HFpEF remain substantial.
Do GLP1 receptor agonists improve clinical outcomes and symptoms in patients with heart failure with preserved ejection fraction?
Do GLP1 receptor agonists improve clinical outcomes and symptoms in patients with heart failure with preserved ejection fraction?
GLP1 receptor agonists offer a promising therapeutic strategy for obesity-related HFpEF by improving symptoms, functional capacity, and clinical outcomes through multiple mechanistic pathways beyond weight loss.
GLP-1 RAs improve symptoms and reduce HF events in obesity-related HFpEF; extends SGLT2i/MRA data with a new therapeutic option.
More than half of cases of heart failure (HF) now occur with preserved ejection fraction (HFpEF), a heterogeneous syndrome strongly influenced by comorbidities such as obesity, hypertension, diabetes and atrial fibrillation. Despite recent evidence supporting SGLT2 inhibitors and mineralocorticoid receptor antagonists, morbidity and mortality remain substantial. GLP1 receptor agonists, initially developed for type 2 diabetes, induce profound weight loss and have demonstrated benefits across cardiovascular, renal and metabolic pathways relevant to HFpEF. Recent randomized controlled trials (RCTs) in obesity-related HFpEF showed clinically meaningful improvements in symptoms, functional capacity and inflammatory biomarkers with semaglutide in STEP-HFpEF, and a reduction in the composite of cardiovascular death or worsening HF events with tirzepatide in SUMMIT. Mechanistic evidence suggests effects on natriuresis, inflammation, cardiac remodelling, endothelial function and epicardial adipose tissue quality and volume. This review summarizes the pathophysiological rationale, clinical evidence, mechanistic insights and therapeutic positioning of GLP1 receptor agonists in HFpEF.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). GLP1 receptor agonists was evaluated. GLP1 receptor agonists improve symptoms, functional capacity, and inflammatory biomarkers, and reduce cardiovascular death or worsening heart failure events in patients with obesity-related HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: